3ZO Stock Overview
A clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Acurx Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.06 |
| 52 Week High | US$4.28 |
| 52 Week Low | US$1.04 |
| Beta | -1.72 |
| 11 Month Change | -36.53% |
| 3 Month Change | -44.21% |
| 1 Year Change | n/a |
| 33 Year Change | -71.20% |
| 5 Year Change | n/a |
| Change since IPO | -78.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3ZO | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -17.3% | 1.2% | 1.0% |
| 1Y | n/a | -19.2% | 7.7% |
Return vs Industry: Insufficient data to determine how 3ZO performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 3ZO performed against the German Market.
Price Volatility
| 3ZO volatility | |
|---|---|
| 3ZO Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3ZO's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 3ZO's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 4 | Dave Luci | www.acurxpharma.com |
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia.
Acurx Pharmaceuticals, Inc. Fundamentals Summary
| 3ZO fundamental statistics | |
|---|---|
| Market cap | €19.95m |
| Earnings (TTM) | -€15.53m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.3x
P/E RatioIs 3ZO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3ZO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$16.44m |
| Earnings | -US$16.44m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.97 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 3ZO perform over the long term?
See historical performance and comparison